2025-05-24 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc (RXRX) based on the data you provided, formatted as requested with English reports, numerical summaries, and subsequent analysis.

**Report on Recursion Pharmaceuticals Inc (RXRX)**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to discover, develop, and commercialize novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** RXRX
*   **Cumulative Return (RXRX):** -62.09%
*   **Cumulative Return (VOO):** 12.31%
*   **Divergence:**
    *   Max: 37.8
    *   Min: -76.2
    *   Current: -74.4
    *   Relative Divergence: 1.6

**Analysis:** RXRX has significantly underperformed the S&P 500. The relative divergence of 1.6 indicates that the current divergence is near its historical low relative to the S&P 500 over the analyzed period.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta   | Cap (B) |
| :----------- | :------ | :----- | :------- | :----- | :------ |
| 2021-2023  | 5.0%    | 73.6%  | 1.0%     | -0.1   | 4.0     |
| 2022-2024  | 0.0%    | 73.6%  | -17.0%   | -0.1   | 2.8     |
| 2023-2025  | -11.0%   | 77.2%  | -38.0%   | -0.1   | 1.7     |

**Analysis:**
* **CAGR:** The Compound Annual Growth Rate shows a declining trend, indicating worsening performance over the periods.
* **MDD:** The Maximum Drawdown is consistently high, indicating significant risk and volatility.
* **Alpha:** The negative and decreasing Alpha values suggest RXRX is underperforming relative to its benchmark, even after accounting for market risk.
* **Beta:** The Beta is slightly negative, suggesting a weak inverse correlation with the market.  This is unusual and could indicate the stock's price movements are not closely tied to the overall market.
* **Cap (B):** Declining capitalization reflects decreased valuation over these periods.

**2. Recent Price Action**

*   **Closing Price:** 4.08
*   **Last Market:** {'price': 4.08, 'previousClose': 4.145, 'change': -1.57} (-1.57% change)
*   **5-Day Moving Average:** 4.276
*   **20-Day Moving Average:** 4.691
*   **60-Day Moving Average:** 5.4429

**Analysis:** The stock is trading below all its key moving averages, indicating a short-term and medium-term downtrend. The recent price drop of -1.57% signals continued downward pressure.

**3. Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.365 (Low Risk)
*   **RSI:** 36.84 (Oversold territory)
*   **PPO:** -0.5512
*   **Recent (20-day) Relative Divergence Change:** 0.1 (Short-term Increase)
*   **Expected Return (%):** -1478.0%

**Analysis:**
* **MRI:** Indicates low market risk.
*   **RSI:** An RSI of 36.84 suggests the stock may be oversold and could be due for a bounce.
*   **PPO:** The negative PPO confirms the downward trend.
*   **Recent Relative Divergence Change:** Positive, suggest a possible short term increase.
*   **Expected Return:** The significantly negative expected return suggests very high risk or potentially flawed model predictions. This is alarming.

**4. Recent News & Significant Events**

*   **[2025-05-22]:** Major business developments, regulatory changes, or market events.
*   **[2025-05-20]:** Analysts discussing performance in context of industry trends and global economic factors.
*   **[2025-05-24]:** Notable stock volatility.
*   **[2025-05-21]:** Market experts highlighting risks and opportunities, advising monitoring of news.

**Analysis:** Recent news suggests that RXRX is experiencing volatility and is subject to market scrutiny. Investors should closely monitor news and company announcements.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출     |
| :--------- | :----- | :------- |
| 2025-05-05 | -0.5   | 0.01 B$  |
| 2024-11-06 | -0.34  | 0.03 B$  |
| 2024-08-08 | -0.4   | 0.01 B$  |
| 2024-05-09 | -0.39  | 0.01 B$  |
| 2025-05-05 | -0.39  | 0.01 B$  |

**Analysis:** The company has consistently reported negative EPS (Earnings Per Share). Revenue is relatively low and unstable. This indicates a lack of profitability.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
| :--------- | :------- | :------------ |
| 2025-03-31 | $0.01B  | -47.31%      |
| 2024-12-31 | $0.00B  | -183.62%     |
| 2024-09-30 | $0.03B  | 53.69%       |
| 2024-06-30 | $0.01B  | 36.14%       |
| 2024-03-31 | $0.01B  | 17.23%       |

**Capital and Profitability:**

| Quarter    | Equity   | ROE       |
| :--------- | :-------- | :-------- |
| 2025-03-31 | $0.93B   | -21.68%  |
| 2024-12-31 | $1.03B   | -17.29%  |
| 2024-09-30 | $0.52B   | -18.27%  |
| 2024-06-30 | $0.58B   | -16.69%  |
| 2024-03-31 | $0.40B   | -22.78%  |

**Analysis:**
* **Revenue and Profitability:** While some quarters show positive profit margins, others are deeply negative. Revenue is inconsistent.
* **Capital and Profitability:** Equity fluctuates, but the Return on Equity (ROE) is consistently negative, indicating the company is not generating profits from its equity.

**7. Overall Analysis**

Recursion Pharmaceuticals Inc. (RXRX) is facing significant challenges.

*   **Poor Performance:** The stock has substantially underperformed the S&P 500.
*   **Downtrend:** The stock is in a downtrend, trading below key moving averages.
*   **Financial Issues:**  The company is experiencing negative EPS, inconsistent revenue, and negative ROE, indicating profitability issues.
*   **Volatility:** Recent news highlights stock volatility and market scrutiny.
*   **High Risk:** The extremely negative expected return (if accurate) warrants significant caution. While the RSI indicates a potential oversold condition, this may not be sufficient to trigger a sustained recovery.
*   **Inconsistent Profitability:** Profit margins and revenue fluctuate widely.

**Recommendation:** Based on the provided data, RXRX appears to be a high-risk investment. The company's negative earnings, high volatility, and underperformance relative to the S&P 500 raise significant concerns. Further due diligence is strongly recommended before considering an investment.
